Posted On: 06/30/2014 4:38:43 PM
Post# of 30038
The Company has had 3 posters accepted for presentation ( analytical performance, LP001 retrospective 7 year patient record clinical performance data, and LP002 2014 clinical performance ) at the Alzheimer’s Association International Conference (AAIC) this July in Copenhagen under the direction of Dr. Louis Kirby and Paul Jorgensen. Our primary focus will be the data of the LP001 retrospective patient record study currently underway with our collaborator’s facility at Banner Sun Health Research Institute in Phoenix, AZ. We believe this data will be the most compelling for Key Opinion Leaders (KOLs) and pharmaceutical companies, our target market for the initial launch of LymPro, as this will provide longitudinal data regarding LymPro’s performance and diagnostic integrity. -
This may be "certain data" we see this week.
The Company is contemplating withholding the release of the LP002 clinical performance data until our #C4CT Concussion Awareness Summit, which will focus on TBI-induced Alzheimer’s disease, at the United Nations on July 31st. http://www.thechairmansblog.com/amarantus-bio...WyCln.dpuf
MANF data could be any of the on the interim data mentioned in the blog or the final report on the Chinese study, a study entitled "MANF Inhibits Tau Hyperphosphorylation in Cultured Neuronal Cells" published in the journal Chinese Pharmacological Bulletin, the authors demonstrated that MANF had a pronounced effect in reducing tau hyperphosphorylation, reducing cell death, and improving overall cellular health in a preclinical models. Misfolded tau is a significant part of the pathophysiology of Alzheimer's disease and Chronic Traumatic Encephalopathy (CTE).
Either of these applications would be of interent at #C4CT or AAIC.
This may be "certain data" we see this week.
The Company is contemplating withholding the release of the LP002 clinical performance data until our #C4CT Concussion Awareness Summit, which will focus on TBI-induced Alzheimer’s disease, at the United Nations on July 31st. http://www.thechairmansblog.com/amarantus-bio...WyCln.dpuf
MANF data could be any of the on the interim data mentioned in the blog or the final report on the Chinese study, a study entitled "MANF Inhibits Tau Hyperphosphorylation in Cultured Neuronal Cells" published in the journal Chinese Pharmacological Bulletin, the authors demonstrated that MANF had a pronounced effect in reducing tau hyperphosphorylation, reducing cell death, and improving overall cellular health in a preclinical models. Misfolded tau is a significant part of the pathophysiology of Alzheimer's disease and Chronic Traumatic Encephalopathy (CTE).
Either of these applications would be of interent at #C4CT or AAIC.
(0)
(0)Scroll down for more posts ▼
